Simplify Your mRNA Workflow From The Start

mRNA therapeutics and vaccines place intense demands on the quality, speed, and reliability of starting materials. Conventional plasmid‑based DNA templates can introduce unnecessary complexity through bacterial contamination risk, variable polyA tails, and additional enzymatic processing steps that slow development. A cell‑free synthetic DNA template offers a more streamlined foundation for mRNA manufacturing.

By feeding directly into in vitro transcription, this approach eliminates the need for linearization or polyA tailing, while delivering high purity, stable polyA sequences, and consistent performance. The result is higher mRNA yields from lower DNA input, reduced process risk, and workflows better aligned with clinical and commercial requirements. With configurations designed to support discovery through GMP production, this technology enables developers to simplify their mRNA workflows while meeting rigorous regulatory and safety expectations.

Explore the full application note to see how rethinking DNA templates can unlock more efficient mRNA production.